Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

NCT03508947 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: WVE-210201
DRUG: Placebo

Sponsor

Wave Life Sciences Ltd.